The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.La présente invention concerne des constructions telles que des molécules d'anticorps comprenant un domaine de liaison spécifique à CD45, ledit domaine de liaison comprenant la SEQ ID NO : 1, 2, 3 et/ou la SEQ ID NO: 4, 5 et 6. L'invention concerne également des compositions pharmaceutiques comprenant lesdites constructions et l'utilisation desdites constructions/compositions d'anticorps dans le traitement.
